Garret FitzGerald, MD, FRS
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa.
Dr. FitzGerald is investigating prostaglandins, a type of biochemical signaling fat, as a novel therapy for high blood pressure and atherosclerosis.
Garret FitzGerald, MD, FRS, is Professor and Chair of Pharmacology, McNeil Professor in Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa.
Dr. FitzGerald is exploring the role of prostaglandin (PG) F2α in blood pressure regulation and atherosclerosis. PGF2α is a lipid autacoid product of PGG/H synthase that activates the F prostanoid (FP) receptor. FP deletion reduces blood pressure coincident with reduction in plasma renin, angiotensin II and aldosterone and retards atherogenesis. Dr. FitzGerald and his colleagues have synthesized compounds and assessed their displacement of PGF2α-induced inositol phosphate generation in human vascular smooth muscle cells and the blockade of the acute PGF2α-induced blood pressure response in mice.
Dr. FitzGerald aims to refine the potency, duration of action and patent position of the lead compound, seek evidence for an antihypertensive effect, develop assays to characterize the pharmacokinetic/dynamic relationships under chronic dosing conditions and seek evidence for FP-antagonism effects on atherogenesis and atherosclerosis.
These studies may establish proof of concept for a novel therapeutic modality for the treatment of hypertension and atherosclerosis.
Dr. FitzGerald earned his medical degree at the University College Dublin. He has received numerous honors, including the 2013 Grand Prix Scientifique from the Lefoulon-Delalande Foundation of the Institute of France, the world’s most prestigious award in cardiovascular research. He is a member of the Institute of Medicine and a Fellow of the Royal Society.